Biodesix grabbed $8.3 million in Series E financing to help boost sales and marketing efforts for its personalized medicine-focused lung cancer test.
Narges Bani Asadi, founder and CEO of Bina Technologies By Narges Bani Asadi One of the elements lacking in the personalized medicine discussion today is the perspective of clinicians and...
Sysmex and Bayer struck a deal that takes personalized medicine yet another step forward. The Japanese diagnostics giant and the German drugmaker will develop companion diagnostic tests designed for targeted cancer tumor treatments. Neither side is disclosing financial details, but they'll carry out their agreement through subsidiaries.
Quintiles, the world's largest CRO, has launched a study to determine whether preprofiling cancer patients for key biomarkers can ease trial enrollment and speed drug development.
Roche's Ventana Medical Systems division will link up with Germany's Boehringer Ingelheim to develop companion diagnostic tests for new cancer drugs. Neither side is disclosing financial details, but the deal is the latest example of how personalized medicine now routinely links the drug development and diagnostics worlds.
New York's Exosome Diagnostics will enlist Mount Sinai Medical Center's research expertise to concoct new molecular diagnostics focused on cancer, inflammation and other diseases that don't rely on tissue biopsies.
A cadre of researchers, academics, insurers and patient advocates are calling for major reform in how tumor biomarker tests are regulated, reimbursed and developed. They argue that the current system leaves the diagnostic tools chronically underused and holds back the advance of personalized cancer care.
Researchers from the U.S. and China have developed statistical models that simulate a drug's reaction in a patient, an innovation that could help deliver treatments to specific disease targets.
Investor interest in biotech is enjoying a prosperous comeback, leading industry watchers and journalists to seek reasons for the frenzy. In The New York Times ' DealBook post, one of the recurring themes among the high-flying drug developers, was a focus on personalized medicine.
In a mixed decision, the Supreme Court has ruled that companies can not obtain a patent on human genes. But companies like Myriad Genetics will be able to nail down patent protection on complementary gene work, or cDNA, which requires human tinkering.